

33. Padma-Nathan H, Yeager JL. An integrated analysis of alprostadil topical cream for the treatment of erectile dysfunction in 1732 patients. *Urology*. 2006; 68(2): 386–391.
34. Sokolakis I, Hatzichristodoulou G. Clinical studies on low intensity extracorporeal shockwave therapy for erectile dysfunction: a systematic review and meta-analysis of randomised controlled trials. *Int J Impot Res*. 2019; 31(3): 177–194.
35. Capogrosso P, Frey A, Jensen CFS, et al. Low-Intensity Shock Wave Therapy in Sexual Medicine-Clinical Recommendations from the European Society of Sexual Medicine (ESSM). *J Sex Med*. 2019; 16(10): 1490–1505.
36. Kitrey ND, Gruenwald I, Appel B, et al. Penile Low Intensity Shock Wave Treatment is Able to Shift PDE5i Nonresponders to Responders: A Double-Blind, Sham Controlled Study. *J Urol*. 2016; 195(5): 1550–1555.
37. Bechara A, Casabé A, De Bonis W, Ciciclia PG. Twelve-Month Efficacy and Safety of Low-Intensity Shockwave Therapy for Erectile Dysfunction in Patients Who Do Not Respond to Phosphodiesterase Type 5 Inhibitors. *Sex Med*. 2016; 4(4): e225–e232.
38. Vinay J, Moreno D, Rajmil O, Ruiz-Castañe E, Sanchez-Curbelo J. Penile low intensity shock wave treatment for PDE5I refractory erectile dysfunction: a randomized double-blind sham-controlled clinical trial. *World J Urol*. 2021; 39(6): 2217–2222.
39. Kalyvianakis D, Mykoniatis I, Memmos E, et al. Low-intensity shockwave therapy (LiST) for erectile dysfunction: a randomized clinical trial assessing the impact of energy flux density (EFD) and frequency of sessions. *Int J Impot Res*. 2020; 32(3): 329–337.
40. Chung E, Cartmill R. Evaluation of Long-Term Clinical Outcomes and Patient Satisfaction Rate Following Low Intensity Shock Wave Therapy in Men With Erectile Dysfunction: A Minimum 5-Year Follow-Up on a Prospective Open-Label Single-Arm Clinical Study. *Sex Med*. 2021; 9(4): 100384.
41. Levine LA, Dimitriou RJ. Vacuum constriction and external erection devices in erectile dysfunction. *Urol Clin North Am*. 2001; 28(2): 335–41.
42. Yuan J, Hoang AN, Romero CA, et al. Vacuum therapy in erectile dysfunction – science and clinical evidence. *Int J Impot Res*. 2010; 22(4): 211–219.
43. Cookson MS, Nadig PW. Long-term results with vacuum constriction device. *J Urol*. 1993; 149(2): 290–294.
44. Lewis RW, Witherington R. External vacuum therapy for erectile dysfunction: use and results. *World J Urol*. 1997; 15(1): 78–82.
45. Trost LW, Munarriz R, Wang R, Morey A, Levine L. External Mechanical Devices and Vascular Surgery for Erectile Dysfunction. *J Sex Med*. 2016; 13(11): 1579–1617.
46. Shabsigh R, Padma-Nathan H, Gittleman M, et al. Intracavernous alprostadil alfadex is more efficacious, better tolerated, and preferred over intraurethral alprostadil plus optional actis: a comparative, randomized, crossover, multicenter study. *Urology*. 2000; 55(1): 109–113.
47. Coombs PG, Heck M, Guhring P, Narus J, Mulhall JP. A review of outcomes of an intracavernosal injection therapy programme. *BJU Int*. 2012; 110(11): 1787–1791.
48. Porst H, Burnett A, Brock G, et al. SOP conservative (medical and mechanical) treatment of erectile dysfunction. *J Sex Med*. 2013; 10(1): 130–171.
49. Eardley I, Donatucci C, Corbin J, et al. Pharmacotherapy for erectile dysfunction. *J Sex Med*. 2010; 7(1 Pt 2): 524–540.
50. Lakin MM, Montague DK, VanderBrug Medendorp S, Tesar L, Schover LR. Intracavernous injection therapy: analysis of results and complications. *J Urol*. 1990; 143(6): 1138–1141.
51. Gupta R, Kirschen J, Barrow RC 2nd, Eid JF. Predictors of success and risk factors for attrition in the use of intracavernous injection. *J Urol*. 1997; 157(5): 1681–1686.